Rune Labs is a precision neurology software and data company whose core products include the StrivePD care-delivery ecosystem and the StriveStudy clinical development platform. Since launching in 2021, the company says StrivePD has become the most widely used software by Parkinson’s patients and clinicians and connects patients to clinical trials. In 2022 Rune’s StrivePD ecosystem received FDA 510(k) clearance to collect patient symptom data, including tremors and dyskinesia, via measurements made by Apple Watch. Rune leverages longitudinal real-world datasets and a network of engaged clinicians and patients to support biopharma and device developers, and has announced partnerships with BlueRock Therapeutics and Aspen Neuroscience. The company reports adopting generative AI tools to provide personalized insights at scale and focuses on delivering actionable data to drive patient engagement and improved care management. Financially, Rune announced a $12 million strategic round that brings total capital raised to over $42 million. Rune Labs is a San Francisco, CA-based brain data company focused on enabling the advancement and delivery of precision neuroscience therapeutics. Led by founder and CEO Brian Pepin, Rune’s precision brain data software platform integrates electrophysiology, brain imaging, device data, wearable data and clinical labels to make brain data useful at scale. The platform is designed to provide researchers, drug developers, and clinicians with tools to guide treatment, uncover hidden disease phenotypes, and design targeted therapies. Rune targets precision medicines for Parkinson’s disease, multiple sclerosis, depression and other neurodegenerative disorders. The company partners with academic collaborators and with biopharma and medtech companies to optimize clinical care and enable development of targeted treatments. Rune raised $22.8M in a Series A financing to expand the number of patients, clinicians, and researchers using its platform; Justin Butler of Eclipse will join the board. Rune Labs develops a cloud-based platform that sequences, labels and analyzes brain imaging and electrophysiology data to support neuroscience therapeutics. The company focuses on device-based neuromodulation therapies such as Deep Brain Stimulation (DBS) and Transcranial Magnetic Stimulation (TMS). Its platform can aggregate longitudinal data across patients, studies and centers and apply machine learning tools, and it interoperates with systems from Medtronic, Abbott and consumer devices like Apple Watch. Rune Labs emphasizes HIPAA compliance and partners with med‑tech and pharma companies as well as academic centers to improve precision therapy delivery. The company plans to use recent funding to continue R&D and to develop additional products. Since its 2018 founding, Rune Labs has raised a total of $7.3 million.

Total raised

$40M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2024